| Next 10 |
Ad
ADTX Articles ADiTx Therapeutics Inc.
home / stock / adtx / adtx articles
Articles | ADiTx Therapeutics Inc. (NASDAQ:ADTX)
-
Shares of Domino’s Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results. The...
- Why Chuy's Holdings Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket | Benzinga
Shares of Chuy’s Holdings, Inc. (NASDAQ:CHUY) rose sharply in today's pre-market trading after the company and Darden Restaurants, Inc. ...
-
U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling over 1% on Wednesday. The Dow traded up 0.53% to 41,173.41 while t...
-
Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-i...
-
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 200 points on Wednesday. The Dow traded up 0.50% to 41,160...
-
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling around 300 points on Wednesday. Following the market opening Wednes...
-
Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss. Stryve Foods post...
-
Aditxt, Inc. (NASDAQ:ADTX) shares are volatile Tuesday after the company announced it will acquire Appili Therapeutics. The Details: Aditxt’s...
-
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and...
Stock Information
Get ADTX Alerts
News, Short Squeeze, Breakout and More Instantly...
ADiTx Therapeutics Inc. Company Name:
ADTX Stock Symbol:
NASDAQ Market:
-0.56% G/L:
$1.63 Last:
89,992 Volume:
$1.80 Open:
$1.63 Close:
ADiTx Therapeutics Inc. Website:
Ad
-
2025-05-02 09:40:00 ET Aditxt (NASDAQ: ADTX) announced that Chief Innovation Officer Dr. Shahrokh Shabahang and Adimune Co-CEO Dr. Friedrich Kapp will participate in today’s Aditxt Weekly Update to discuss recent progress on ADI-100 , the lead therapeutic candidate of its wholly ...
-
Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Sy...
-
Aditxt, Inc. requests that their press release NewsItemId: 20250417385764 “Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimu...